Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October 2018. Because it competes with three previously approved anti-IL-5 agents (GlaxoSmithKline’s Nucala, Teva’s Cinqair, and AstraZeneca’s Fasenra) for the eosinophilic asthma patient population and with an anti-IgE agent Xolair (Roche) for a subset of severe allergic and eosinophilic asthmatics, physician assessment of Dupixent’s performance will provide Sanofi and Regeneron, their competitors, and companies developing therapies targeting severe asthma with insight regarding its market uptake.

This Asthma Emerging Therapies series tracks the awareness, trial, and use of Dupixent by U.S. pulmonologists and allergists over a year’s time. Additionally, the series examines physician-anticipated trends in asthma treatment, particularly Dupixent’s uptake, and assesses Sanofi’s and Regeneron’s promotional efforts.

QUESTIONS ANSWERED

  • What are U.S. pulmonologists’ and allergists’ awareness of, familiarity with, and perceptions of Dupixent?
  • Among prescribers of Dupixent, to which patients are they prescribing it, what are the reasons for prescribing it, and how satisfied are they with Dupixent?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with other recent products for asthma?

Geography

  • United States

Primary Research

  • Survey of approximately 75 U.S. pulmonologists and allergists for each wave

Key Metrics Included

  • Unaided and aided awareness of Dupixent
  • Familiarity with and impressions of Dupixent
  • Prescriber and nonprescriber profiles
  • Willingness to prescribe Dupixent
  • Performance of Dupixent on key attributes
  • Sales representative visit frequency, reach, and effectiveness
  • Benchmarking against previously launched agents

PRODUCT DESCRIPTION

Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Instructions for uploading your PowerPoint presentation and survey:

  1. The PPT attachment needs to be the first node under the report (i.e., it should appear before your survey).

  2. Name the PPT in the same fashion as you want it displayed on the Platform. The name will be displayed exactly as it appears in the filename. We recommend using the following naming convention for the PPT filename: Indication – Product – Report. The name in the “Title” field in the Form tab should be the same as the PPT.

  3. Select the “Embed” option in the "EmbedAttachment" field for the PPT attachment. This will ensure that it is embedded on the Platform.

  4. The survey should be uploaded to Kentico as a File Attachment after the PPT attachment. The survey should be in PDF in the DRG survey document.  The name in the “Title” field in the Form tab should be the same as the survey.

  5. Select the “Sidebar” option in the "EmbedAttachment" field for the survey attachment.

  6. For the Abstract field: Copy/Paste the key inputs from the product brochure, per guidance from Marketing.

Table of contents

  • Asthma - Emerging Therapies - Dupixent (Dupilumab) (US) Wave 2
    • Asthma Emerging Therapies Dupixent US Wave 2 (June 2019)

Author(s): Shubhendu Ghosh, PhD

Shubhendu Ghosh, Ph.D., is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma.

Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.


Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details